Similar articles

• Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia.

  Nozue T, Michishita I, Mizuguchi I. Nozue T, et al. J Atheroscler Thromb. 2010 Feb;17(1):37-44. doi: 10.5551/jat.1651. Epub 2010 Jan 14. J Atheroscler Thromb. 2010. PMID: 20075599 Clinical Trial.
• Beneficial effects of ezetimibe-based therapy in patients with dyslipidemia.

  Miura S, Saku K. Miura S, et al. J Cardiol. 2008 Aug;52(1):1-6. doi: 10.1016/j.jjcc.2008.05.001. Epub 2008 Jun 30. J Cardiol. 2008. PMID: 18639771 Review.
• Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk Guideline-based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC).

  Katz PM, Mendelsohn AA, Goodman SG, Langer A, Teoh H, Leiter LA. Katz PM, et al. Can J Cardiol. 2011 Mar-Apr;27(2):138-45. doi: 10.1016/j.cjca.2010.12.010. Can J Cardiol. 2011. PMID: 21459260
• Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.

  Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD. Saougos VG, et al. Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2236-43. doi: 10.1161/ATVBAHA.107.147280. Epub 2007 Jul 26. Arterioscler Thromb Vasc Biol. 2007. PMID: 17656665 Clinical Trial.
• The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes?

  Rizzo M, Rini GB, Spinas GA, Berneis K. Rizzo M, et al. Atherosclerosis. 2009 Jun;204(2):330-3. doi: 10.1016/j.atherosclerosis.2008.10.005. Epub 2008 Oct 14. Atherosclerosis. 2009. PMID: 19027905 Review.